BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Chicago Area’s Life Sciences Scene Continues Making an Impression

  While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the Chicago market should be a growth spot in the coming years. Chicago Biomedical Consortium and COUR Pharmaceuticals executives share what makes the area a hot spot.

  January 30, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Business

  The Patient’s Perspective with Tom Whitehead

  In this episode, presented by the Genscript Biotech Global Forum 2025, BioSpace’s Head of Insights Lori Ellis talks to Tom Whitehead, co-founder of the Emily Whitehead Foundation, about how standard care, cell and gene therapies and their impact on patients.

  January 30, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Neurodegenerative disease

  Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data

  Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.

  January 30, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
  

  Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

  January 30, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Government

  At Confirmation Hearing, RFK Jr. Downplays Anti-Vax Concerns

  Kennedy’s confirmation hearing on Wednesday became heated as Democratic senators grilled the nominee for HHS Secretary on his previous statements about vaccine safety.

  January 30, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Roche to Stay ‘Disciplined’ With Deals in 2025

  For 2025, Roche will continue a careful approach to high-priced deals, putting science at the center of its business development decisions, executives said Thursday.

  January 30, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings

  Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.

  January 30, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  FDA

  FDA Approves Vertex’s Journavx as First New Pain Drug in Decades

  The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

  January 30, 2025

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Layoffs

  Cargo Halts CAR T Trial, Lays Off 50% of Workforce in Pipeline Reset

  CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.

  January 30, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Layoffs

  Ironwood Chops Half of Staff as 2025 Guidance Disappoints

  The layoffs will allow Ironwood to dedicate more resources to pushing its lead molecule apraglutide through a Phase III trial and a rolling NDA submission.

  January 30, 2025

   · 

  1 min read

   · 

  Tristan Manalac